Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Safety and Immunogenicity Study of NWRD06 in Hepatocellular Carcinoma Patients After Radical Resection

NCT06088459 is registered in ClinicalTrials.gov with Newish Technology (Beijing) Co., Ltd. as lead sponsor.

NCT NCT06088459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06088459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Safety and Immunogenicity Study of NWRD06 in Hepatocellular Carcinoma Patients After Radical Resection
Lead sponsor
Newish Technology (Beijing) Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2023
Completion date
June 30, 2025
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma